Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Y. Negi · SciRah

Researcher profile · Semantic Scholar

Y. Negi

Share profile

Y. Negi — researcher profile on SciRah

h-index: 9
Works: 47
Citations: 226

Most-cited papers

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
Hayato Kawachi, Tadaaki Yamada, M. Tamiya, Y. Negi +18 more
2023JAMA Network Open34 citations Open access
Semantic Scholar
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
E. Fujimoto, T. Kijima, K. Kuribayashi, Y. Negi +5 more
2017Expert Review of Anticancer Therapy30 citations
Semantic Scholar
Tumor‐associated macrophage‐derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma
D. Horio, T. Minami, H. Kitai, H. Ishigaki +16 more
2020Cancer Science23 citations Open access
Semantic Scholar
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest.
H. Ishigaki, T. Minami, O. Morimura, H. Kitai +13 more
2019Biochemical and Biophysical Research Communications - BBRC19 citations
Semantic Scholar
Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report
E. Fujimoto, T. Yokoi, K. Mikami, Shingo Kanemura +9 more
2018Case Reports in Oncology12 citations Open access
Semantic Scholar
Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma
Yasuhiro Nakajima, K. Kuribayashi, H. Ishigaki, A. Tada +7 more
2020Cancer Investigation10 citations
Semantic Scholar
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma
Y. Negi, K. Kuribayashi, N. Funaguchi, H. Doi +6 more
2018In Vivo10 citations Open access
Semantic Scholar
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
Naoya Nishioka, Hayato Kawachi, T. Yamada, M. Tamiya +21 more
2024Frontiers in Immunology9 citations Open access
Semantic Scholar
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
Hayato Kawachi, T. Yamada, M. Tamiya, Y. Negi +19 more
2024Oncoimmunology9 citations Open access
Semantic Scholar
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
Daisuke Hazama, K. Nakahama, Hiroaki Kodama, A. Miyazaki +17 more
2023JTO Clinical and Research Reports9 citations Open access
Semantic Scholar
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
A. Tada, T. Minami, H. Kitai, Yoko Higashiguchi +13 more
2023Lung Cancer8 citations Open access
Semantic Scholar
KEYNOTE‐A17: First‐Line Pembrolizumab Plus Cisplatin–Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma
Takashi Kijima, T. Kato, Y. Goto, K. Kuribayashi +8 more
2025Cancer Science6 citations Open access
Semantic Scholar
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
Naoya Nishioka, T. Hata, T. Yamada, Yasuhiro Goto +20 more
2024Cancer research and treatment : official journal of Korean Cancer Association6 citations Open access
Semantic Scholar
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%
Shota Takei, Hayato Kawachi, T. Yamada, M. Tamiya +19 more
2024Frontiers in Immunology5 citations Open access
Semantic Scholar
Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
Shohei Watanabe, K. Yoshizumi, Sayaka Moriguchi, T. Higashiyama +3 more
2021eNeurologicalSci5 citations Open access
Semantic Scholar
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
Y. Tachibana, K. Morimoto, T. Yamada, Hayato Kawachi +19 more
2024Investigational new drugs4 citations
Semantic Scholar
Successful Management of Steroid‐Refractory Immune‐Related Pneumonitis With Mycophenolate Mofetil: A Case Report
H. Ota, Daichi Fujimoto, Y. Negi, T. Murata +9 more
2025Respirology Case Reports3 citations Open access
Semantic Scholar
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
T. Hata, T. Yamada, Y. Goto, Akihiko Amano +19 more
2025Cancer Research Communications3 citations Open access
Semantic Scholar
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study
Ryo Sawada, T. Yamada, Y. Goto, Y. Negi +13 more
2025Translational Lung Cancer Research3 citations Open access
Semantic Scholar
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
K. Morimoto, Tadaaki Yamada, Hayato Kawachi, M. Tamiya +18 more
2023Targeted oncology3 citations
Semantic Scholar
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan
S. Goda, T. Yamada, K. Morimoto, T. Hata +20 more
2023Translational Lung Cancer Research3 citations Open access
Semantic Scholar
Efficacy and safety of nivolumab for malignant mesothelioma in the real world.
K. Mikami, T. Yokoi, R. Takahashi, E. Shibata +10 more
20203 citations
Semantic Scholar
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)
Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Takeyasu Yuki +46 more
2025Therapeutic Advances in Medical Oncology2 citations Open access
Semantic Scholar
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression
Hayato Kawachi, T. Hata, T. Yamada, Y. Goto +19 more
2025Translational Lung Cancer Research2 citations Open access
Semantic Scholar
Sarcomatoid Malignant Pleural Mesothelioma Associated with Anti-Ma2-Related Paraneoplastic Neurological Syndrome: A Case Report
A. Tada, K. Kuribayashi, Kazuhiro Kitajima, A. Nakamura +10 more
2023Current Problems in Cancer: Case Reports2 citations Open access
Semantic Scholar
Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report.
Y. Negi, K. Kuribayashi, H. Doi, N. Funaguchi +6 more
2018Molecular and clinical oncology2 citations Open access
Semantic Scholar
Clinical Significance of Bone Metastases in Pleural Mesothelioma
Mitsutomi Miyake, K. Kuribayashi, Hiroshi Doi, Aki Kubota +10 more
2025Thoracic Cancer1 citations Open access
Semantic Scholar
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
T. Hata, T. Yamada, Y. Goto, Akihiko Amano +19 more
2025Clinical Lung Cancer1 citations Open access
Semantic Scholar
Challenges for the development of immunotherapy in small-cell lung cancer
T. Minami, Y. Kinehara, O. Morimura, H. Kitai +8 more
20181 citations
Semantic Scholar
ERRATUM: Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study.
Naoya Nishioka, T. Hata, T. Yamada, Y. Goto +20 more
2026Cancer research and treatment : official journal of Korean Cancer Association0 citations Open access
Semantic Scholar
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis
Masashi Ishihara, T. Kawamura, Yukiko Namba, Takeyasu Yuki +48 more
2026JTO Clinical and Research Reports0 citations Open access
Semantic Scholar
Clinical course of non-small cell lung cancer with concurrent MET exon 14 skipping and KRAS G12C mutations treated with sequential targeted therapies: a case report
Y. Hasegawa, Daichi Fujimoto, Tetsushi Maesako, Mayuko Tokuda +10 more
2026International Journal of Lung Cancer0 citations Open access
Semantic Scholar
Identification of Hidden Cachexia Subgroup in PD‐L1‐High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria
Naoya Nishioka, Hayato Kawachi, T. Yamada, M. Tamiya +17 more
2026Journal of Cachexia, Sarcopenia and Muscle0 citations Open access
Semantic Scholar
Abstract 1583: Galectin9 targeted therapy for aiming cure in oncogenic driver alterations-positive non-small cell lung cancer
Takanori Kondo, Toshiyuki Minami, H. Kitai, Yoko Higashiguchi +15 more
2026Cancer Research0 citations
Semantic Scholar
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy
Y. Kunimatsu, Naoya Nishioka, T. Yamada, Hayato Kawachi +16 more
2025Translational Lung Cancer Research0 citations Open access
Semantic Scholar
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
A. Sasada, Hayato Kawachi, T. Yamada, T. Hata +19 more
2025Anticancer Research0 citations
Semantic Scholar
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
T. Hata, T. Yamada, Y. Goto, Akihiko Amano +19 more
2025Lung Cancer0 citations Open access
Semantic Scholar
Abstract 3730: Impact of proton pump inhibitor on ICI with or without chemotherapy for NSCLC with high PD-L1 TPS
Ryo Sawada, Hayato Kawachi, T. Yamada, M. Tamiya +12 more
2024Cancer Research0 citations
Semantic Scholar
Abstract 3729: Association between clinical characteristics and treatment outcome of immune checkpoint inhibitor with or without chemotherapy in elderly non-small cell lung cancer patients with high PD-L1 expression
Hayato Kawachi, Shota Takei, T. Yamada, M. Tamiya +13 more
2024Cancer Research0 citations
Semantic Scholar
P18-5 Examination of the sequence of chemotherapy regimen in malignant pleural mesothelioma
Y. Negi, Taiichiro Otsuki, N. Kawamura, M. Murakami +13 more
2023Annals of Oncology0 citations Open access
Semantic Scholar
P2.06-08 Nivolumab for Malignant Mesothelioma: A Real-World Experience
Maiko Niki, T. Yokoi, R. Takahashi, K. Mikami +10 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P2.01-112 Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab
E. Shibata, T. Yokoi, R. Takahashi, K. Mikami +9 more
2018Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P3.03-016 Association between the Stainability of the Neurofibromatosis Type 2 Gene-Related Protein Merlin and the Tumor Properties of Mesotheliomas: Topic: Mesothelioma Transitional
K. Kuribayashi, Y. Koda, Y. Negi, E. Fujimoto +5 more
20170 citations Open access
Semantic Scholar
582PFirst-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
E. Fujimoto, K. Kuribayashi, Shingo Kanemura, Y. Negi +6 more
20170 citations Open access
Semantic Scholar
P3.03-032 PET/CT for Patients with Very Early Clinical Stage of Malignant Pleural Mesothelioma: When Can PET/CT Detect Tumor Growth of T0/T1a Mesothelioma?: Topic: Mesothelioma Clinical
Y. Negi, K. Kuribayashi, E. Fujimoto, Y. Koda +5 more
20170 citations Open access
Semantic Scholar
537PClinical utility of 18F-FDG PET for chemotherapy response evaluation in patients with malignant pleural mesothelioma
Shingo Kanemura, K. Kuribayashi, E. Fujimoto, Y. Negi +5 more
20170 citations Open access
Semantic Scholar
273P Cisplatin in combination with pemetrexed in the treatment of patients for advanced malignant peritoneal mesothelioma: Retrospective study of 21 cases
K. Shingo, K. Kuribayashi, E. Fujimoto, Y. Koda +5 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Kuribayashi×24
Invite
K. Kuribayashi — researcher profile on SciRah
Takashi Kijima×21
Invite
Takashi Kijima — researcher profile on SciRah
Y. Chihara×19
Invite
Y. Chihara — researcher profile on SciRah
S. Shiotsu×18
Invite
S. Shiotsu — researcher profile on SciRah

×17

Invite

T. Yamada — researcher profile on SciRah

Invite

T. Kijima — researcher profile on SciRah

Invite

K. Mikami — researcher profile on SciRah

Invite

T. Minami — researcher profile on SciRah

Hayato Kawachi×16

Invite

Hayato Kawachi — researcher profile on SciRah

Koichi Takayama×15

Invite

Koichi Takayama — researcher profile on SciRah

Invite

A. Okada — researcher profile on SciRah

Invite

T. Yokoi — researcher profile on SciRah